BIOMOTION PHARMA ApS: Financial statements 2022
CVR: 12928203
Source: annual report 2022, Danish Business Authority
01/10/2021 – 30/09/2022
BIOMOTION PHARMA ApS (CVR 12928203) has filed annual accounts for 2022. In 2022, the company reported revenue of DKK 16,000 and a net result of DKK 6,200 compared with DKK 3,750 the year before. The profit margin was 38.8%. Equity in the 2022 report amounted to DKK 11,200. The solvency ratio was 90%.
- Revenue
- DKK 16,000
- Gross Profit
- DKK 6,200
- Profit/Loss
- DKK 6,200
- Equity
- DKK 11,200
- Total Assets
- DKK 12,450
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 16 t. | 6 t. | 6 t. | 11 t. | - |
| 2021 | - | -1 t. | 4 t. | 5 t. | - |
| 2020 | - | -1 t. | -1 t. | 1 t. | - |
| 2019 | - | -2 t. | -2 t. | 3 t. | - |
| 2018 | - | 5 t. | 5 t. | 4 t. | - |
Official annual report
Keep an eye on BIOMOTION PHARMA ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout BIOMOTION PHARMA ApS
BIOMOTION PHARMA ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 1989. The company is in liquidation. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named HANDEL OG INVESTERING AF 1989 ApS and DANSK FARMASAN A/S. The management consists of Michael Rasmussen. The company is owned by Michael Rasmussen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -4,000 and a net result of DKK -4,202 compared with DKK -6,460 the year before. Equity in the 2025 report amounted to DKK -892.